http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2544982-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b6d6b0a9721d7b7ca7d5f368df0f3658 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-65 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-27 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-27 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
| filingDate | 2010-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e0ed84d217fc3cd5e81b769043c46ce http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d82153004eaafb1b2d92b6a72c64a966 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e560bd5ac76ed648e3ba0b662bf5a8ff |
| publicationDate | 2015-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2544982-T3 |
| titleOfInvention | Method to predict the level of growth response |
| abstract | A method of predicting the level of response to growth hormone treatment in an individual who is deficient in growth hormone (GHD), the method comprising the steps of: a. identify that the individual has: - the AA genotype in cyclin-dependent kinase 4 (CDK4) _rs2270777; or - allele A at the leptin receptor (LEPR) _rs970467; b. identify the standard deviation score (SDS) of insulin-like growth factor I (IGF-I) at the starting point of the treatment ("IGF-I_SDS_B"); c. adjust treatment compliance as a percentage of expected dose / planned dose during the first month of treatment ("compliance"); d. measure the SDS of the weight at the starting point of the treatment ("bl_wt SDS"); and. adjust the prescribed average dose of growth hormone in μg / kg body weight / day ("dose"); F. provide age in years ("age"); and g. calculate the predicted SDS of IGF-I after one month of growth hormone treatment with the formula IGF-I_SDS_1M> = - 4.7265 + (0.7065 x IGF-I_SDS_B) + (0.0423 x "compliance" ) + (0.2446 x bl_wt SDS) + (0.0402 x "dose") + (0.057 x "age"), where the predicted level of response is used to optimize a compliance and treatment plan, provided that all the identification and measurement steps are carried out in vitro. |
| priorityDate | 2009-09-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 291.